scholarly journals Androgen receptor corepressors and prostate cancer

2006 ◽  
Vol 13 (4) ◽  
pp. 979-994 ◽  
Author(s):  
Craig J Burd ◽  
Lisa M Morey ◽  
Karen E Knudsen
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Steroid Hormones ◽  
Regulatory Mechanisms ◽  
Cancer Growth ◽  
Tumor Type ◽  
Concerted Effort ◽  
Androgen Action ◽  
Prostate Cancers

The androgen receptor (AR) mediates the effects of male steroid hormones (androgens) and contributes to a wide variety of physiological and pathophysiological conditions. As such, the regulatory mechanisms governing AR activity are of high significance. Concerted effort has been placed on delineating the mechanisms that control AR activity in prostate cancer, as AR is required for survival and proliferation in this tumor type. Moreover, AR is the central therapeutic target for metastatic prostate cancers, and recurrent tumors evade therapy by restoring AR activity. It is increasingly apparent that AR cofactors which modulate receptor activity can contribute to prostate cancer growth or progression, and this has been particularly well established for AR coactivators. The present review is focused on the role of AR corepressors in governing androgen action, with a specific emphasis on their activities in prostate cancer.

scholarly journals Androgen receptor antagonists for prostate cancer therapy

2014 ◽  
Vol 21 (4) ◽  
pp. T105-T118 ◽  
Author(s):  
Christine Helsen ◽  
Thomas Van den Broeck ◽  
Arnout Voet ◽  
Stefan Prekovic ◽  
Hendrik Van Poppel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Practice ◽  
Androgen Receptor ◽  
Metastatic Prostate Cancer ◽  
Castration Resistant ◽  
Androgen Action ◽  
Conflicting Evidence ◽  
Prostate Cancer Therapy ◽  
Androgen Receptor Antagonists

Androgen deprivation is the mainstay therapy for metastatic prostate cancer (PCa). Another way of suppressing androgen receptor (AR) signaling is via AR antagonists or antiandrogens. Despite being frequently prescribed in clinical practice, there is conflicting evidence concerning the role of AR antagonists in the management of PCa. In the castration-resistant settings of PCa, docetaxel has been the only treatment option for decades. With recent evidence that castration-resistant PCa is far from AR-independent, there has been an increasing interest in developing new AR antagonists. This review gives a concise overview of the clinically available antiandrogens and the experimental AR antagonists that tackle androgen action with a different approach.

scholarly journals The role of androgen receptor coactivators in prostate cancer growth

2000 ◽  
Vol 3 (S1) ◽  
pp. S38-S38 ◽  
Author(s):  
SS Taneja
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Cancer Growth

scholarly journals Androgens and androgen receptor signaling in prostate tumorigenesis

2014 ◽  
Vol 54 (1) ◽  
pp. R15-R29 ◽  
Author(s):  
Ye Zhou ◽  
Eric C Bolton ◽  
Jeremy O Jones
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Cancer Cells ◽  
Cancer Growth ◽  
Castration Resistant Prostate Cancer ◽  
Prostate Cancer Cells ◽  
Prostate Tumorigenesis ◽  
Prostate Development ◽  
Cancer Initiation

Androgens and androgen receptor (AR) signaling are necessary for prostate development and homeostasis. AR signaling also drives the growth of nearly all prostate cancer cells. The role of androgens and AR signaling has been well characterized in metastatic prostate cancer, where it has been shown that prostate cancer cells are exquisitely adept at maintaining functional AR signaling to drive cancer growth. As androgens and AR signaling are so intimately involved in prostate development and the proliferation of advanced prostate cancer, it stands to reason that androgens and AR are also involved in prostate cancer initiation and the early stages of cancer growth, yet little is known of this process. In this review, we summarize the current state of knowledge concerning the role of androgens and AR signaling in prostate tissue, from development to metastatic, castration-resistant prostate cancer, and use that information to suggest potential roles for androgens and AR in prostate cancer initiation.

The role of androgen receptor in glucose transporters expression in prostate cancer cells

2015 ◽  
Author(s):  
Pedro Gonzalez-Menendez ◽  
David Hevia ◽  
Juan C Mayo ◽  
Rosa M Sainz
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Cancer Cells ◽  
Glucose Transporters ◽  
Prostate Cancer Cells

scholarly journals Interplay Between SOX9, Wnt/β-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer

2019 ◽  
Vol 20 (9) ◽  
pp. 2066 ◽  
Author(s):  
Namrata Khurana ◽  
Suresh C. Sikka
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Signaling Pathways ◽  
Critical Role ◽  
Castration Resistant Prostate Cancer ◽  
Form Complex ◽  
Androgen Receptor Signaling ◽  
Castration Resistant ◽  
Signaling Axis

Androgen receptor (AR) signaling plays a key role not only in the initiation of prostate cancer (PCa) but also in its transition to aggressive and invasive castration-resistant prostate cancer (CRPC). However, the crosstalk of AR with other signaling pathways contributes significantly to the emergence and growth of CRPC. Wnt/β-catenin signaling facilitates ductal morphogenesis in fetal prostate and its anomalous expression has been linked with PCa. β-catenin has also been reported to form complex with AR and thus augment AR signaling in PCa. The transcription factor SOX9 has been shown to be the driving force of aggressive and invasive PCa cells and regulate AR expression in PCa cells. Furthermore, SOX9 has also been shown to propel PCa by the reactivation of Wnt/β-catenin signaling. In this review, we discuss the critical role of SOX9/AR/Wnt/β-catenin signaling axis in the development and progression of CRPC. The phytochemicals like sulforaphane and curcumin that can concurrently target SOX9, AR and Wnt/β-catenin signaling pathways in PCa may thus be beneficial in the chemoprevention of PCa.

scholarly journals Novel Interaction between the Co-chaperone Cdc37 and Rho GTPase Exchange Factor Vav3 Promotes Androgen Receptor Activity and Prostate Cancer Growth

2012 ◽  
Vol 288 (8) ◽  
pp. 5463-5474 ◽  
Author(s):  
Fayi Wu ◽  
Stephanie O. Peacock ◽  
Shuyun Rao ◽  
Sandra K. Lemmon ◽  
Kerry L. Burnstein
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Rho Gtpase ◽  
Receptor Activity ◽  
Cancer Growth ◽  
Exchange Factor ◽  
Androgen Receptor Activity
Sign in / Sign up

Export Citation Format

Share Document